Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785292 | 0.85 | PTPN5 (0.41) | ALDH1A1KDM4EPDE2ADEGS1ESR1 | |
| SCHEMBL13852045 | 0.78 | IDO1 (0.39) | ALDH1A1KDM4EPDE2ADEGS1ACHE | |
| SCHEMBL12602992 | 0.78 | CHRNA7 (0.41) | MAPTTDP1PDE2ADEGS1ACHE | |
| SCHEMBL10194742 | 0.78 | IDO1 (0.39) | ALDH1A1KDM4EPDE2ADEGS1ACHE | |
| SCHEMBL7899070 | 0.76 | ESR1 (0.62) | MEN1MAPTKMT2AALDH1A1TDP1 | |
| SCHEMBL15575588 | 0.76 | CYP2A6 (0.38) | ALDH1A1DEGS1ESR1ESR2POLB | |
| SCHEMBL13852046 | 0.76 | ADRB2 (0.50) | MEN1KMT2ATDP1DEGS1ESR1 | |
| SCHEMBL34472369 | 0.76 | TAAR1 (0.54) | PDE2ADEGS1ESR1ESR2 | |
| SCHEMBL34472200 | 0.76 | PDE2A (0.46) | PDE2ADEGS1ESR1ESR2 | |
| SCHEMBL8090925 | 0.75 | TAAR1 (0.41) | ALDH1A1KDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111321480-B | Low-dielectric polyimide fiber, preparation method and application | 航天科工(长沙)新材料研究院有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-114230790-A | Polyimide powder and preparation method thereof | 长沙新材料产业研究院有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-111321480-A | Low-dielectric polyimide fiber, preparation method and application | 长沙新材料产业研究院有限公司 | 2020-06-23 | — | — | CN | claimed |
| CN-111321480-B | Low-dielectric polyimide fiber, preparation method and application | 航天科工(长沙)新材料研究院有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114230790-A | Polyimide powder and preparation method thereof | 长沙新材料产业研究院有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-111321480-A | Low-dielectric polyimide fiber, preparation method and application | 长沙新材料产业研究院有限公司 | 2020-06-23 | — | — | CN | disclosed |
| US-8338603-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20120108642-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. | 2012-05-03 | — | — | US | disclosed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | disclosed |
| EP-1581225-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040176443-A1 | Capsaicin receptor ligands | NEUROGEN CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-6723730-B2 | DIARYL PIPERAZINES AND RELATED COMPOUNDS USEFUL IN THE TREATMENT OF A CHRONIC AND ACUTE PAIN CONDITIONS, ITCH AND URINARY INCONTINENCE. | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | disclosed |
| EP-1301484-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020132853-A1 | Capsaicin receptor ligands | NEUROGEN CORPORATION | 2002-09-19 | — | — | US | disclosed |
| WO-2002008221-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176443-A1 | Capsaicin receptor ligands | TRPV1, TRPV5, TRPV2 | MEN1 4876/4885MAPT 3250/4885KMT2A 3839/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | MEN1 4577/4885MAPT 3949/4885KMT2A 2232/4885 |
| US-20120108642-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV5, TRPV3 | MEN1 3210/4885MAPT 1809/4885KMT2A 3985/4885 |
| US-20020132853-A1 | Capsaicin receptor ligands | TRPV1, TRPV5, TRPV2 | MEN1 4876/4885MAPT 3250/4885KMT2A 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.